1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides

BACKGROUND: Plazomicin (PLZ) is an aminoglycoside recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections, including pyelonephritis. We evaluated the susceptibility (S) rates of PLZ, amikacin (AMK), gentamicin (GEN) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sader, Helio S, Arends, S J Ryan, Gogtay, Jaideep, Carvalhaes, Cecilia G, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776425/
http://dx.doi.org/10.1093/ofid/ofaa439.1461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776425/
http://dx.doi.org/10.1093/ofid/ofaa439.1461

Ejemplares similares